Nordic Nanovector to present preclinical studies with 212Pb-NNV003, a novel CD37-specific Targeted Alpha Therapy for CLL and NHL, at TRP 2019
Oslo, Norway, 6 June 2019 Nordic Nanovector ASA (OSE: NANO) announces that its Chief Scientific Officer, Jostein Dahle, will present results from preclinical studies with 212PB-NNV003, a novel Targeted Alpha Therapy comprising its proprietary CD37-specific antibody (NNV003) coupled with the alpha-particle generating radioisotope lead-212 (212Pb) in models of chronic lymphocytic leukaemia (CLL) and non-Hodgkin lymphoma (NHL) at the Targeted Radiopharmaceuticals Summit taking place in Munich, Germany on 12-13 June. The presentation will take place at 13th June 09:30-10:00 CEST and is